{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Lomecel-B",
            "NStudiesAvail": 430108,
            "NStudiesFound": 5,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 5,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Plasma levels of interleukins measured in pg/mL.",
                              "Change in Clinical Frailty rating",
                              "Change in risk of falling",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Number of participants that die from any cause while enrolled on the trial and after being treated with LMSCs.",
                              "Change by participant-reported outcomes. Minimum 16 (no concern about falling) to maximum 64 (severe concern about falling)",
                              "Plasma levels of B & T Cells.",
                              "Distance in meters walked in 6 minutes",
                              "Short Physical Performance Battery Assessment",
                              "TInetti POMA assessment",
                              "Weigh measurements at visits",
                              "Handgrip strength via dynamometer."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:",
                              "Differences in rate of decline from Aging Frailty",
                              "Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment",
                              "PROMIS Short Form 20a questionnaire",
                              "PROMIS Mobility questionnaire",
                              "PROMIS Upper Extremity questionnaire",
                              "Short Form 36 questionnaire",
                              "IIEF questionnaire",
                              "SQOL-F questionnaire",
                              "Death from any cause",
                              "Falls Efficacy Scale-International (FES-I)",
                              "Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:",
                              "Rate of decline in Aging Frailty status as assessed by the 6 minute walk test",
                              "Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)",
                              "Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test",
                              "Rate of decline in Aging Frailty status as assessed by the Weight Loss",
                              "Rate of decline in Aging Frailty status as assessed by the Handgrip Test"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Within 12 months after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function. Measured by serial echocardiograms and MRI.",
                              "Used to assess change in somatic growth.",
                              "Used to assess change in somatic growth.",
                              "Used to assess change in somatic growth.",
                              "Treatment-Emergent Adverse Events will be assessed via incidence of co-morbidity, which include: cardiovascular morbidity; need for transplantation; re-hospitalizations; cardiovascular mortality; and all-cause mortality."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy: Change from baseline in right ventricular ejection fraction (%).",
                              "Efficacy: Change from baseline in right ventricular end-systolic volume.",
                              "Efficacy: Change from baseline in right ventricular end-diastolic volume.",
                              "Efficacy: Change from baseline in right ventricular end-diastolic diameter.",
                              "Efficacy: Change from baseline tricuspid regurgitation.",
                              "Efficacy: Change in weight (in kilograms).",
                              "Efficacy: Change in height (in centimeters).",
                              "Efficacy: Change in head circumference (in centimeters).",
                              "Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Neurological/neurocognitive assessments. ADAS-Cog 11 (Alzheimer's Disease Assessment Scale-cognitive subscale 11) MMSE (Mini Mental State Examination) NPI (Neuropsychiatric Inventory) UPSIT (University of Pennsylvania Smell Identification Test) GDS (Geriatric Depression Scale)\nQuality of life assessments. ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) QOL-AD (Quality of Life-Alzheimer's Disease)\nBlood inflammatory and AD biomarkers. IL-1 IL-6 TGF-\u03b21 TNF-\u03b1 CRP D-Dimer Fibrinogen ApoE\nCerebrospinal fluid (CSF) inflammatory biomarkers. IL-1 IL-6 TGF-\u03b21 TNF-\u03b1\nCSF biomarkers of AD. Tau. Phosphorylated tau. Beta-amyloid.\nBrain volumetry calculated using MRI, including:\n\nHippocampal volume. Ventricular volume. Whole-brain volume."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At Baseline, 2, 4, 13, 26, 39, and 52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02600130"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Geometric mean titer",
                              "Change in overall assessment via Lung imaging via chest X-ray will be assessed and compared between baseline and 6 months",
                              "Change in overall assessment via Lung imaging via computerized tomography will be assessed and compared between baseline and 6 months"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Immunity",
                              "Change in Imaging via X-ray",
                              "Change in Imaging via Computerized Tomography"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to 6 Months",
                              "Baseline to 6 Months",
                              "Baseline to 6 Months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "7UG3HL148318-02",
                              "1U24HL148316-01A1"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/7UG3HL148318-02",
                              "https://reporter.nih.gov/quickSearch/1U24HL148316-01A1"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract",
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Efficacy will be reported as change in right ventricular ejection fraction (RVEF) assessed as a percentage and will be measured via cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as change in right ventricular mass index at diastole assessed as g/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as change in right ventricular end diastolic volume index (RVEDVI) assessed as ml/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as change in right ventricular end systolic volume index (RVESVI) assessed as ml/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as change in right ventricular global longitudinal strain and strain rate assessed as % and s^-1 respectively and will be measured via serial cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as the change in right ventricular global circumferential strain and strain rate as % and s^-1 respectively, and will be measured via serial cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as the change in right atrial volume index as ml/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as the change in right ventricular work index as (mmHg x mL x beats) / min and will be measured via serial cardiac magnetic resonance (CMR) imaging.",
                              "Efficacy will be reported as change in the categorical qualitative assessment of tricuspid valve regurgitation (trivial, mild, moderate, severe) and will be measured via transthoracic echocardiography.",
                              "Efficacy will be reported as change in diastolic function as measured by the tricuspid E/E' ratio, evaluating the tricuspid inflow E and A velocities and ratio, and tricuspid annular DTI E'A' velocities. Function reported as normal diastolic function (no abnormalities in these measures), mildly impaired diastolic function (1 abnormal measure), moderately impaired diastolic function (2 abnormal measures), and severely impaired diastolic function (3 abnormal measures). These measures will be measured via transthoracic echocardiography.",
                              "Efficacy measured as change in participant's weight in kg and will be measured serially to assess change in somatic growth.",
                              "Efficacy measured as change in participant's length (height) in cm and will be measured serially to assess change in somatic growth.",
                              "Efficacy measured as change in participant's head circumference in cm and will be measured serially to assess change in somatic growth.",
                              "Efficacy measured as change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) in pg/ml and will be measured serially by blood draw.",
                              "The Ross Heart Failure Classification provides a global assessment of heart failure severity in infants. Efficacy measured as change in classification and will be measured serially via physician's assessment using the modified Ross Heart Failure Classification; classifications defined as Class 1 (no limitations of physical activity); Class 2 (may experience symptoms during moderate exercise but not during rest); Class 3 (symptoms with minimal exertion that interfere with normal daily activity); Class 4 (unable to carry out physical activity/has symptoms at rest that worsen with exertion).",
                              "The PedsQL\u2122 Infant Scales is a generic health related quality of life instrument specifically for healthy and ill infants ages 1-24 months. Efficacy measured as change in PedsQL total improvement score and will be measured serially by parental proxy-report. Higher scores are indicative of better quality of life.",
                              "Efficacy measured as the number and percentage of participants who do not undergo unplanned catheter interventions to address pulmonary arteries or the aorta.",
                              "Efficacy measured as change in biomarkers/cytokines in pg/ml and/or ng/ml and will be measured serially by blood draw.",
                              "Safety will be reported as the number of participants experiencing treatment emergent serious adverse events (TE-SAEs) assessed by treating physician within the 30 days following study procedure. These include: greater than 30 seconds of sustained/symptomatic ventricular tachycardia requiring intervention; cardiogenic shock; unplanned cardiovascular operation for bleeding due to right ventricular intramyocardial injection site bleeding in the first five days after stage II palliation; worsening of cardiac function; local infection or systemic infection; need for new permanent pacemaker; death.",
                              "Safety will be reported as the number of participants with adjudicated events including cardiovascular morbidity; need for transplantation; re-hospitalizations; cardiovascular mortality; all-cause mortality."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in right ventricular ejection fraction (RVEF)",
                              "Change in right ventricular mass index at diastole",
                              "Change in right ventricular end-diastolic volume index (RVEDVI)",
                              "Change in right ventricular end-systolic volume index (RVESVI)",
                              "Change in right ventricular global longitudinal strain and strain rate",
                              "Change in right ventricular global circumferential strain and strain rate",
                              "Change in right atrial volume index",
                              "Change in right ventricular work index",
                              "Change in tricuspid regurgitation severity",
                              "Change in RV compliance/diastolic function",
                              "Change in weight",
                              "Change in length (height)",
                              "Change in head circumference",
                              "Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)",
                              "Change in modified Ross Heart Failure Classification score",
                              "Change in PedsQL\u2122 Infant Scales",
                              "Freedom from unplanned catheter intervention needed to address the pulmonary arteries or aorta.",
                              "Change in biomarkers/cytokines",
                              "Participants experiencing treatment emergent serious adverse events (TE-SAEs)",
                              "Participants experiencing major adverse cardiac events (MACE)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 6 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "Baseline, 12 Months",
                              "30 days post Stage II palliation",
                              "Baseline, 12 Months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "ELPIS II study website",
                              "Earlier phase I study (ELPIS)"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.elpistrial.org",
                              "https://clinicaltrials.gov/ct2/show/NCT03525418"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04925024"
                        ]
                  }
            ]
      }
}